Skip to main navigation
FivePrime Logo
  • Sitemap
  • Careers
  • Contact
  • Company
    • Management
    • Board of Directors
    • Scientific Advisors
    • Investors
    • Strategic Collaborations
    • Careers
    • Contact Us
  • Pipeline
    • Cabiralizumab (FPA008)
    • Bemarituzumab (FPA144)
    • FPA150
    • Immuno-Oncology
  • Platform
    • Protein Library
    • Proprietary Screens
  • News & Media
    • Press Releases
  • Publications
  • Investors

    Investor Relations

    • Press Releases
    • Corporate Governance
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Contact
Investors

Investor Relations

  • Press Releases
  • Corporate Governance
  • Events & Presentations
  • Financial Information
  • Stock Information
  • Investor Contact

Shareholder Tools

  • print page
  • contact IR
  • rss feeds
  • email alerts
Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter
Print   Share
Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter

Email Alert Subscription

* Required fields

Unsubscribe from all Five Prime Therapeutics email alerts

Copyright Nasdaq. Minimum 15 minutes delayed.

Exchange
Price
Change (%)
Volume

  • Company
    • Management
    • Board of Directors
    • Scientific Advisors
    • Investors
    • Strategic Collaborations
    • Careers
    • Contact Us
  • Pipeline
    • Cabiralizumab (FPA008)
    • Bemarituzumab (FPA144)
    • FPA150
    • Immuno-Oncology
  • Platform
    • Protein Library
    • Proprietary Screens
  • News & Media
    • Press Releases
  • Publications
  • Investors
    • Press Releases
    • Corporate Governance
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Contact
© 2018 Five Prime Therapeutics, Inc.    All rights reserved
  • Legal Notice
  • Privacy Policy
Website Design: Hane Chow, Inc.